Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA (ACR Convergence 2024) - Sep 25, 2024 - Abstract #1546; Pres time: Nov 17, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "Among patients who had a record of ≥1 LN treatment following index diagnosis (n=1878), the initial treatment regimen included ≥1 of the following: oral/intravenous corticosteroids (n=1106; 58.9%), antimalarials (n=900; 47.9%), immunosuppressants including mycophenolate mofetil (n=807; 43.0%), antihypertensives (n=699; 37.2%), B-cell therapies including belimumab (n=128; 6.8%), calcineurin inhibitors including voclosporin (n=52; 2.8%) and sodium-glucose cotransporter-2 inhibitors (n=9; 0.5%). Time from index LN diagnosis to treatment was shorter for patients diagnosed on/after January 1, 2021, than those diagnosed before, suggesting a potential movement toward earlier treatment in recent years. This will be explored for specific treatments in future analyses. Further work will investigate LN treatment patterns beyond the initial regimen including line of therapy and switching, as well as treatment in relation to the updated KDIGO 2024 guidelines and by..."
Claims database • Retrospective data • Glomerulonephritis • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Oncology • Renal Disease • Respiratory Diseases • Tuberculosis
|
|
Anisha M. Patel1; Carmen Ng1; Lisa Lindsay1; Zhiyu Xia2; William F. Pendergraft III3; Maria Dall'Era4
|